

Curriculum Vitae

Personal information **Irene Bidault**

Work experience

1. Employer: Pharmacovigilance and Poison Control Center - PARIS- Hopital Fernand-Widal

- Start date : 11/1987
- End date : 09/1994
- Position : Associate physician
- Activities :

at the pharmacovigilance centre :

* management of spontaneous reports of adverse effects including pregnancy exposure cases

* participation in the national pharmacovigilance survey committee

* participation in pharmacovigilance training

* responding to questions from different healthcare professionals about drug use

* bibliographic research at the French Centre for Toxicological Information based on requests from healthcare professionals

- at the poison control centre :

* phone assistance : information and recommendation for acute poisoning treatment (medicines, industrial products, food, pesticides, cosmetics) but also during chronic poisoning (occupational pathology, toxicovigilance).

* education and training

* participation in the congresses of the Poison control centres.

* validation of the adverse effects module of a french database "Thériaque" for the following areas : toxicology and neuropsychiatry overdose.

2. Employer : AFSSAPS then ANSM

- Start date: 10/1994
- End date: current
- Position : Vigilance assessor
- Activities :

-> 1994 – 2000 : pharmacovigilance assessor for specific drugs

* evaluation of safety data for medicinal products registered in a national or european procedure for the therapeutic range of anti-infectives (including vaccines and AIDS drugs) and anti-cancer drugs

* participation in the various working groups and commissions at national and european level

-> 2000 - 2012 : pharmacovigilance and regulatory assessor

* daily evaluation of serious adverse effect notifications from marketing authorisation holders (signal detection)

* coordination and monitoring of drug pharmacovigilance in compassionate use programs

* participation in French institutional vigilances coordination meetings

* active (pilot) participation in the European benchmarking of drug agencies (2008/2009)

* crisis management : member of the "2009-2010 flu pandemic" crisis unit, "Mediator crisis" in November 2010

-> 2012 – 2017 : Vigilance assessor for reception and orientation of vigilance reports :

• prioritization of vigilance reports (pharmacovigilance, vigilance of clinical trials, medication errors and materiovigilance)

• management of so-called "alert" messages in the context of exchanges with the alert department of the ministry of health and other institutions on alerts, sensitive information and border products

• support for the development of regulatory texts, best practices, procedures, website update documents, news for the vigilance bulletin

• business reference for the preparatory work of the current portal for reporting health events by patients and healthcare professionals

-> June 2017 – ongoing : attached to the "signal management" division

• Evaluation of potential pharmacovigilance signals including cases of medication errors, non-

compliant use and signals identified in the medical literature

- Signal detection
- Participation in the management of alerts
- Management of a specific committee for the management of signals with the participation of the network of regional pharmacovigilance centres, healthcare professionals and patient associations

Education and training

1. Subject:

1989 PhD in medicine
1987 diploma of studies in Toxicology and Clinical Pharmacology. Paris VII University
1985/1987 Internship in General Medicine
1977/1985 Medical studies at the Faculty of Paris V (Paris - Ouest)
1977 Baccalaureate C.

Additional information

Publications

1. Strengthened Pharmacovigilance in France for Monitoring COVID-19 Vaccines and Therapeutics Toward a New Surveillance Era?. Page A., Levraut M., Ferard C., Mehdi B., Bidault I., Pierron E., Jacquot B., Mounier C. Drug Safety. Conference: 21st Annual Meeting of the International Society of Pharmacovigilance, ISoP 2022. Verona Italy. 45(10) (pp 1187-1188), 2022. Date of Publication: October 2022. [Conference Abstract] DOI: <https://dx.doi.org/10.1007/s40264-022-01219-7>
2. Validation and Reproducibility of the Updated French Causality Assessment Method: An Evaluation by Pharmacovigilance Centres & Pharmaceutical Companies. Theophile H., Dutertre J.-P., Gerardin M., Valnet-Rabier M.-B., Bidault I., Guy C., Haramburu F., Hillaire-Buys D., Meglio C., Arimone Y. Therapie. 70(5) (pp 465-476), 2015. Date of Publication: 01 Sep 2015. [Article] PMID: 26423144 [https://www.ncbi.nlm.nih.gov/pubmed/?term=26423144] DOI: <https://dx.doi.org/10.2515/therapie/2015028>
3. Accuracy and reproducibility of the updated French causality assessment method: A comparison using evaluators from pharmacovigilance centres and pharmaceutical companies. Theophile H., Dutertre J.P., Gerardin M., Valnet-Rabier M.-B., Bidault I., Guy C., Haramburu F., Hillaire-Buys D., Meglio C., Arimone Y. Fundamental and Clinical Pharmacology. Conference: 18th Annual Meeting of French Society of Pharmacology and Therapeutics, 81th Annual Meeting of Society of Physiology, 35th Pharmacovigilance Meeting, 15th APNET Seminar, 12th CHU CIC Meeting and 9th Annual Meeting of Physiology, Pharmacology and Therapeut. Poitiers France. Conference Publication: (var.pagings). 28(SUPPL. 1) (pp 103), 2014. Date of Publication: May 2014 [Conference Abstract] DOI: <https://dx.doi.org/10.1111/fcp.12066>
4. Updating the French method for the causality assessment of adverse drug reactions. Arimone Y., Bidault I., Dutertre J.-P., Gerardin M., Guy C., Haramburu F., Hillaire-Buys D., Meglio C., Penfornis C., Theophile H., Valnet-Rabier M.-B. Therapie. 68(2) (pp 69-76), 2013. Date of Publication: March-April 2013. PMID: 23773347 [https://www.ncbi.nlm.nih.gov/pubmed/?term=23773347] DOI: <https://dx.doi.org/10.2515/therapie/2013016>
5. Baclofen and alcohol dependence: A treatment at risk?. Saviuc P., Garnier R., Bidault I., Manel J. Clinical Toxicology. Conference: 2012 International Congress of the European Association of Poisons Centres and Clinical Toxicologists, EAPCCT 2012. London United Kingdom. Conference Publication: (var.pagings). 50(4) (pp 350), 2012. Date of Publication: April 2012. [Conference Abstract] DOI: <https://dx.doi.org/10.3109/15563650.2012.669957>
6. High doses of trimebutine: A risk of severe poisoning? Pelissier F., Saviuc P., Bidault I., Gibaja V., Sarfati L., Garnier R., Belmahdi F., De Haro L., Lagarce L., Cabot C. Clinical Toxicology. Conference: 2012 International Congress of the European Association of Poisons Centres and Clinical Toxicologists, EAPCCT 2012. London United Kingdom. Conference Publication: (var.pagings). 50(4) (pp 337-338), 2012. Date of Publication: April 2012. [Conference Abstract] DOI: <https://dx.doi.org/10.3109/15563650.2012.669957>
7. Update of the french drug reaction assessment method. Reactualisation de la methode francaise d'imputabilite des effets indesirables des médicaments Arimone Y., Bidault I., Dutertre J.-P., Gerardin M., Guy C., Haramburu F., Hillaire-Buys D., Meglio C., Penfornis C., Theophile H., Valnet-Rabier M.-B. Therapie. 66(6) (pp 517-525), 2011. Date of Publication: November-December 2011. [Article] PMID: 22186077 [https://www.ncbi.nlm.nih.gov/pubmed/?term=22186077] DOI: <https://dx.doi.org/10.2515/therapie/2011073>
8. Causality assessment of adverse drug reaction: Comparison between pharmaceutical industry and pharmacovigilance centre using the updated french causality assessment method. Valnet Rabier M.B., Arimone Y., Bidault I., Dutertre J.P., Gerardin M., Guy C., Haramburu F., Hillaire Buys D., Meglio C., Penfornis C., Theophile H. Drug Safety. Conference: 11th ISoP Annual Meeting 'Next Stop: Istanbul - Bridging the Continents!'. Istanbul Turkey. Conference Publication: (var.pagings). 34(10) (pp 950), 2011. Date of Publication: October 2011. [Conference Abstract]
9. Impact of risk minimisation measures for buflomedil: A 2-year surveillance from the French poison and toxicovigilance centres. Pulce C., Saviuc P., Garnier R., Boucher A., Bidault I. Clinical Toxicology. Conference: 2010 International Congress of the European Association of Poisons Centres and Clinical Toxicologists. Bordeaux France. Conference Publication: (var.pagings). 48(3) (pp 258), 2010. Date of Publication: March 2010. [Conference Abstract] DOI: <https://dx.doi.org/10.3109/15563651003740240>
10. Updating of the French causality assessment method. Arimone Y., Bidault I., Collignon A.E., Dutertre J.P., Gerardin M., Guy C., Haramburu F., Hillaire-Buys D., Loupi E., Meglio C., Penfornis C., Theophile H., Valnet-Rabier M.B. Fundamental and Clinical Pharmacology. Conference: 14th Annual Meeting of the French Society of Pharmacology and Therapeutics, the 77th Annual Meeting of the Society of Physiology, the 31st Pharmacovigilance Meeting, the 11th APNET Seminar and the 8th CHU CIC Meeting. Bordeaux France. Conference Publication: (var.pagings). 24(SUPPL. 1) (pp 6), 2010. Date of Publication: April 2010. [Conference Abstract] DOI: <https://dx.doi.org/10.1111/j.1472-8206.2010.00819.x>
11. Update of the French causality assessment method: Results of the validation phase. Arimone Y., Bidault I., Collignon A.E., Dutertre J.P., Gerardin M., Guy C., Haramburu F., Hillaire-Buys D., Loupi E., Meglio C., Penfornis C., Theophile H., Valnet-Rabier M.B. Drug Safety. Conference: 10th Annual Meeting of the International Society of Pharmacovigilance, ISoP 'Pharmacovigilance in the Global Village'. Accra Ghana. Conference Publication: (var.pagings). 33(10) (pp 938), 2010. Date of Publication: 2010. [Conference Abstract] DOI: <https://dx.doi.org/10.2165/11532470-000000000-00000>

12. Intensive pharmacovigilance monitoring for influenza vaccines and antiviral drugs used during the influenza A(H1N1)v pandemic: The french experience. Jacquet A., Robine I., Durrieu G., Auriche P., Bidault I., Ouaret S., Millaret A., Guy C., Page A., Vial T., Perault-Pochat M.C., Montastruc J.L., Castot A.C., Kreft-Jais C. Drug Safety. Conference: 10th Annual Meeting of the International Society of Pharmacovigilance, ISO 'Pharmacovigilance in the Global Village'. Accra Ghana. Conference Publication: (var.pagings). 33(10) (pp 909-910), 2010. Date of Publication: 2010. [Conference Abstract] DOI: <https://dx.doi.org/10.2165/11532470-000000000-00000>
13. Serious adverse drug reactions : First six months applications of the French pharmacovigilance decree dated 13 March 1995 [2]. Lelouet H., Morin M., Trenque T., Bidault I., Castot A., Alexandre J.M. Therapie. 51(5) (pp 555-556), 1996. Date of Publication: 1996. [Letter] PMID: 9138393 [<https://www.ncbi.nlm.nih.gov/pubmed/?term=9138393>]
14. Complications following absorption of 1,5% glycine irrigating solution: 10 case-reports to the poison control center and pharmacovigilance center of Paris-Fernand-Widal. Bidault I., Maignen F., Estrache M., Castot A. Therapie. 48(5) (pp 498-499), 1993. Date of Publication: 1993.[Conference Paper] PMID: 8146842 [<https://www.ncbi.nlm.nih.gov/pubmed/?term=8146842>]
15. Allergic reactions to drug dyes: Case reports in the literature and in the pharmacovigilance center. Vaudelle C., Belegaud D., Bidault I., Castot A. Therapie. 48(5) (pp 484-485), 1993. Date of Publication: 1993. [Conference Paper] PMID: 8146831 [<https://www.ncbi.nlm.nih.gov/pubmed/?term=8146831>]
16. Acute toxicity of zidovudine: Analysis of 43 overdoses. Maignen F., Meglio S., Bidault I., Castot A. Therapie. 48(2) (pp 129-131), 1993. Date of Publication: 1993. [Short Survey] PMID: 8351681 [<https://www.ncbi.nlm.nih.gov/pubmed/?term=8351681>]
17. Side effects with omeprazole. A survey by the French ADR regional monitoring centres. Castot A., Bidault I., Dahan R., Efthymiou M.L. Therapie. 48(5) (pp 469-474), 1993. Date of Publication: 1993. [Conference Paper] PMID: 8146827 [<https://www.ncbi.nlm.nih.gov/pubmed/?term=8146827>]
18. Analysis of the questions required to a regional ADR monitoring centre. Discussion about a possible computerization. Carlier P., Lagier G., Castot A., Bidault I. Therapie. 45(5) (pp 383-386), 1990. Date of Publication: 1990. [Conference Paper] PMID: 2260029 [<https://www.ncbi.nlm.nih.gov/pubmed/?term=2260029>]
19. Nephrotoxicity of semisynthetic penicillins. A report of 62 cases. Castot A., Carlier P., Bidault I. Therapie. 43(5) (pp 399-403), 1988. Date of Publication: 1988. [Article] PMID: 3227500 [<https://www.ncbi.nlm.nih.gov/pubmed/?term=3227500>]
20. Eosinophilia-myalgia syndrome in France: 24 cases. Castot A., Bidault I., Bournerias I., Carlier P., Efthymiou M.L. Therapie. 46(5) (pp 355-365), 1991. Date of Publication: 1991. [Conference Paper]
21. Allopurinol induced peripheral neuropathy: 5 cases [5]. Castot A., Falcy M., Garnier R., Bidault I., Cronnier A., Efthymiou M.L. Therapie. 46(5) (pp 391-392), 1991. Date of Publication: 1991. [Letter]
22. Does peripheral neuropathy due to allopurinol exist? Analysis of 5 cases. Castot A., Falcy M., Garnier R., Bidault I., Cronnier A., Efthymiou M.L. Therapie. 46(5) (pp 391-392), 1991. Date of Publication: 1991 Sep-Oct. [Letter] PMID: 1661446 [<https://www.ncbi.nlm.nih.gov/pubmed/?term=1661446>]
23. "Eosinophilia-myalgia" syndrome due to L-tryptophan containing products. Cooperative evaluation of French Regional Centers of Pharmacovigilance. Analysis of 24 cases. Castot A., Bidault I., Bournerias I., Carlier P., Efthymiou M.L. Therapie. 46(5) (pp 355-365), 1991. Date of Publication: 1991 Sep-Oct. [Article] PMID: 1754978 [<https://www.ncbi.nlm.nih.gov/pubmed/?term=1754978>]
24. Eosinophilia myalgia syndrome in France. Castot A., Bidault I., Bournerias I., Kreft Jais C., Efthymiou M.L. Post Marketing Surveillance. 5(2) (pp 169-172), 1991. Date of Publication: 1991. [Article]
25. Prospective and retrospective use of criteria for defining serious adverse drug reactions. Bidault I., Castot A., Sabouraud S., Lagier G. Therapie. 45(5) (pp 379-382), 1990. Date of Publication: 1990. [Conference Paper]
26. Liver damage with chronic paracetamol use: 3 cases. Bidault I., Lagier G., Garnier R., Pallot J.L., Larrey D. Therapie. 42(4) (pp 387-388), 1987. [Article] PMID: 3686472 [<https://www.ncbi.nlm.nih.gov/pubmed/?term=3686472>]
27. Does a specific withdrawal syndrome from non dopaminergic antiparkinsonian drugs exist?. George V., Castot A., Bidault I. Therapie. 42(4) (pp 339-341), 1987. Date of Publication: 1987. [Article] PMID: 3686467 [<https://www.ncbi.nlm.nih.gov/pubmed/?term=3686467>]

[Projects](#)

[Memberships](#)

[Other Relevant Information](#)